Gilead Sciences Inc Arcus Biosciences, Inc. (RCUS) insider trading activity

Gilead Sciences Inc is > 10% Shareholder of Arcus Biosciences, Inc.. Currently has a direct ownership of 31.4 Million shares of RCUS, which is worth approximately $281 Million. The most recent transaction as insider was on Feb 18, 2025, when has been sold 1,363,636 shares (Common Stock) at a price of $11.0 per share, resulting in proceeds of $14,999,996. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 31.4M

4.54% 3M change

4.54% 12M change

Total Value Held $281 Million

GILEAD SCIENCES INC Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	BUY Open market or private purchase	$14,999,996 $11.0 p/Share	1,363,636 Added 4.16%	31,424,760 Common Stock
Jan 29 2024	BUY Open market or private purchase	$319,999,995 $21.0 p/Share	15,238,095 Added 33.64%	30,061,124 Common Stock
Jun 28 2023	BUY Open market or private purchase	$19,452,600 $19.26 p/Share	1,010,000 Added 6.38%	14,823,029 Common Stock
Jan 31 2021	BUY Open market or private purchase	$220,350,000 $39.0 p/Share	5,650,000 Added 28.88%	13,913,029 Common Stock

Also insider at

ALVR

Allovir, Inc. Healthcare

> 10% Shareholder

KYTX

Kyverna Therapeutics, Inc.

> 10% Shareholder

XLO

Xilio Therapeutics, Inc. Healthcare

> 10% Shareholder

ASMB

ASSEMBLY BIOSCIENCES, INC. Healthcare

> 10% Shareholder

GSI